Member Info for arsenal58

Your shares are somebody elses worry now Schel
35.9 on the bid now 37 by end of play one would think
There are lots more buyers here than you think !!
Has been said not in a rush patience means more shares at a lower price for the big boys who I think are mopping up the sells slowly but surely ??

No they dont
Utter rubbish just

Agree with them statements entirely red
Thought it was going too go up the Swanee when TD Waterhouse got crushed
No problems at all
Have an account with You invest can be horrendous to sell a busy stock

are now allowing me my full credit allowance to buy SOLG usually a very bullish sign
Rumours are in full flight one would think

II sold me at last for 30000

Lucky you!! hope your not kicking yourself later
Cannot buy any on II
Will buy my lot

Cannot buy a bean on II
False drop occuring
As per

GlaxoSmithKline plc (NYSE:GSK) Expected to Earn FY2020 Earnings of $2.94 Per Share
Posted by Darlene League on Oct 27th, 2020 // Comments off
GlaxoSmithKline logo
GlaxoSmithKline plc (NYSE:GSK) – SVB Leerink decreased their FY2020 earnings per share (EPS) estimates for GlaxoSmithKline in a report released on Wednesday, October 21st. SVB Leerink analyst G. Porges now forecasts that the pharmaceutical company will earn $2.94 per share for the year, down from their previous forecast of $2.96. SVB Leerink also issued estimates for GlaxoSmithKline’s FY2023 earnings at $3.46 EPS and FY2024 earnings at $3.67 EPS.
Get GlaxoSmithKline alerts:
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.01). The business had revenue of $9.46 billion for the quarter, compared to analysts’ expectations of $9.60 billion. GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%.

Several other research analysts have also issued reports on the stock. Credit Suisse Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, October 5th. Morgan Stanley reissued an “underweight” rating on shares of GlaxoSmithKline in a research report on Friday, October 9th. UBS Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, October 12th. Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a report on Friday, September 18th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 21st. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.00.
Shares of GSK stock opened at $35.22 on Monday. The firm has a 50 day moving average of $37.61 and a 200-day moving average of $40.13. The company has a market cap of $88.35 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 2.84 and a beta of 0.65. The company has a quick ratio of 0.69, a current ratio of 0.96 and a debt-to-equity ratio of 1.28. GlaxoSmithKline has a 52 week low of $31.43 and a 52 week high of $48.25.
Several institutional investors have recently bought and sold shares of GSK. Milestone Advisory Partners acquired a new stake in shares of GlaxoSmithKline during the second quarter worth $25,000. Pflug Koory LLC raised its holdings in GlaxoSmithKline by 64.4% in the 3rd quarter. Pflug Koory LLC now owns 781 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 306 shares during the period. Creative Financial Designs Inc. ADV purchased a new position in GlaxoSmithKline during the second quarter worth approximately $31,000. Manches

GlaxoSmithKline plc (NYSE:GSK) Expected to Earn FY2020 Earnings of $2.94 Per SharePosted by Darlene League on Oct 27th, 2020 // Comments offGlaxoSmithKline logoGlaxoSmithKline plc (NYSE:GSK) – SVB Leerink decreased their FY2020 earnings per share (EPS) estimates for GlaxoSmithKline in a report released on Wednesday, October 21st. SVB Leerink analyst G. Porges now forecasts that the pharmaceutical company will earn $2.94 per share for the year, down from their previous forecast of $2.96. SVB Leerink also issued estimates for GlaxoSmithKline’s FY2023 earnings at $3.46 EPS and FY2024 earnings at $3.67 EPS.Get GlaxoSmithKline alerts: GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.01). The business had revenue of $9.46 billion for the quarter, compared to analysts’ expectations of $9.60 billion. GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%.

https://masterinvestor.co.uk/commodities/next-multi-bagger-solomon-gold/Well old but right on the money lol

See you are still in dallo
I re entered at 246 this am
See a lot of interest stateside to come
Did you know Jamie Dimon his in apparently

Want a piece of the action boom

Large sell order caused the drop

There is your answer for the two million buy ?
Odi

Is usually well informed ??
Lets hope its boom time

You believe the Murdoch rag
Arse paper tomorrow

Nice numbers

Strategic asset !!
What a load of cobblers !!!
The SK stands for Smith Kline a good old yankee company
Nobody will stop a American company taking this out !!
You seem to have an agenda with your posts ??
You talk utter bull****e

Jolly
Really sounds expensive to me !!!
Lol

Read this the other day
He seems extremely confident of all three being tier 1
I do hope he his proven right